{"anticipatedPostingDate":"2027-12","denomUnitsSelected":"Participants","description":"CRR: % of participants with BOR of confirmed sCR/CR per IMWG criteria. sCR: CR \\& normal serum free light chain (sFLC) ratio \\& absence of clonal cells in BMB/BMA by IH, IF, or flow cytometry. CR: negative immunofixation on serum \\& urine, disappearance of any soft tissue plasmacytoma \\& \\<5% plasma cells in BMA, if disease measurable by sFLC only, preceding criteria plus normal sFLC ratio.","reportingStatus":"NOT_POSTED","timeFrame":"From date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurred first (up to approximately 20.14 months)","title":"Complete Response Rate as Per IMWG Criteria by Investigator Assessment","type":"SECONDARY"}